uniQure (QURE)
(Delayed Data from NSDQ)
$4.88 USD
-0.04 (-0.81%)
Updated May 13, 2024 04:00 PM ET
After-Market: $4.88 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
uniQure N.V. [QURE]
Reports for Purchase
Showing records 101 - 120 ( 153 total )
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Highlights from the Meeting on the Mesa: Looking Beyond Stem Cells in Regenerative Medicine
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Biotechnology: Sparks a Much Needed Boost for Gene Therapy Stocks
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
OMG! Gene Therapy Could be Pricey- Panic!
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Sanfilippo B Reports Positive Results and Other Upcoming Catalysts; Reiterate Buy Rating and PT of $39
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIN C
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Encouraging Early Read from First-in- Human Gene Therapy for Sanfilippo B
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Risk / Reward Attractive Heading into the Sanfilippo Abstract
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Glybera Is Inconsequential to Any Long Thesis
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
AAV5 Liver Tropisim May Not Be a Wildcard for Hemophilia B
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Additional Cash Ensures Advancement of Multiple Indications
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIN C